drugset / Trial / NCT01129674
A Long-Term, Open-Label, Study on Schizophrenia
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-10
- Completion
- 2012-10
Outcome
Outcome not reported
Stopped: “The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | — | Oral |
| Subject | LY2140023 | Unknown | 20 mg | Oral |
| Subject | LY2140023 | Unknown | 40 mg | Oral |
| Subject | LY2140023 | Unknown | 80 mg | Oral |
| Comparator | Olanzapine | Small molecule | — | Oral |
| Comparator | Quetiapine | Small molecule | — | Oral |
| Comparator | Risperidone | Other / unclassified | — | Oral |